CATX perspectivetherapeutics.com: Enterprise Value to EBITDA Ratio

Brandmark of Perspective Therapeutics (CATX)

Perspective Therapeutics (CATX) production cycles rely on sterile synthesis zones with a strict small-batch schedule and continuous calibration of radiation systems. This EV/EBITDA price chart on GURU.Markets, which currently stands at 0.00, confirms the market valuation and complements data regarding the urgent air transport of isotopes to clinics. Business success is based on the precision of targeted delivery and the successful licensing of new radiopharmaceuticals.

CATX Perspective Tx: Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/10/2026

Metric breakdowns and analytics for perspectivetherapeutics.com (CATX)

- stock price and consensus target price:
Stock Quotes Perspective Therapeutics, Inc.|CATX - Average Forecast Price
- company stock capitalization data:
Market Valuation CATX|CATX - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share Perspective Therapeutics|CATX - Net Asset Value|Market Value to Book Value Ratio perspectivetherapeutics.com|CATX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Perspective Therapeutics|CATX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Perspective Therapeutics, Inc.|CATX - Company Cumulative Indebtedness|Debts to Book Capitalization CATX|CATX - Long-Term Liabilities|Company Short-Term Debt Perspective Therapeutics|Quick Liquidity perspectivetherapeutics.com
- business earnings and investment ratios data:
CATX - Final Profit|Expected Profit Perspective Therapeutics|CATX - Price to Earnings Ratio|Future Price to Earnings Perspective Therapeutics, Inc.|CATX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CATX|CATX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Perspective Therapeutics|CATX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months perspectivetherapeutics.com|CATX - Earnings per share increase in current year|Net earnings per share growth forecast for next year Perspective Therapeutics
General company analysis:Perspective Therapeutics Inc CATX
Product sample of Perspective Tx

Fundamental analysis of credit quality requires separating operational efficiency from the impact of debt load. This metric compares the total enterprise value with earnings before interest, taxes, depreciation, and amortization, determining the payback period of assets. For Perspective Therapeutics (CATX), with its costly radioisotope infrastructure, this calculation is critically important. The price action of the EV/EBITDA debt and operational load metric reflects the real value of Perspective Therapeutics (CATX) while accounting for its technological advantage.

Direct competitors

Geron Corp. - Enterprise Value to EBITDA Ratio|Nanobiotix Group (NBTX) - Company Value to EBITDA|BCYC: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CTMX (cytomx.com)|genelux.com (GNLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio MOLN (Molecular Partners Ltd)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncolytics Biotech, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSTA|EV/EBITDA Multiple MBRX|EV/EBITDA Multiple galeratx.com (GRTX)|Molecular Templates, Inc. - Enterprise Value to EBITDA Ratio